

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 June 2011 (03.06.2011)

(10) International Publication Number
WO 2011/066008 A3

PCT

(51) International Patent Classification:
C12Q 1/68 (2006.01) *G01N 33/15* (2006.01)
C12N 15/31 (2006.01) *C12R 1/32* (2006.01)

(74) Agents: **CHALKER, Daniel J.** et al.; Chalker Flores, LLP, 14951 North Dallas Parkway, Suite 400, Dallas, TX 75254 (US).

(21) International Application Number:
PCT/US2010/046042

(22) International Filing Date:
19 August 2010 (19.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12/628,148 30 November 2009 (30.11.2009) US

(71) Applicants (for all designated States except US): **BAYLOR RESEARCH INSTITUTE** [US/US]; 3310 Live Oak Street, Suite 501, Dallas, TX 75201 (US). **MEDICAL RESEARCH COUNCIL on behalf of THE NATIONAL INSTITUTE FOR MEDICAL RESEARCH** [GB/GB]; The Ridgeway, Mill Hill, London NW7 1AA (GB). **IMPERIAL COLLEGE HEALTHCARE NHS TRUST** [GB/GB]; The Bays, South Wharf Road, St. Mary's Hospital, London W2 1NY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BANCHEREAU, Jacques, F.** [FR/US]; 6730 Northaven Road, Dallas, TX 75230 (US). **CHAUSABEL, Damien** [FR/US]; 4532 Southpointe Drive, Richardson, TX 75082 (US). **O'GARRA, Anne** [GB/GB]; 116 Greenfield Gardens, London NW2 1HY (GB). **BERRY, Matthew** [GB/GB]; 303c West End Lane, London NW6 1RD (GB). **KON, Onn Min** [MY/GB]; 60 Llanvanor Road, London NW2 2AP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:
21 July 2011

(54) Title: BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION



(57) Abstract: The present invention includes methods, systems and kits for distinguishing between active and latent *Mycobacterium tuberculosis* infection in a patient suspected of being infected with *Mycobacterium tuberculosis*, the method including the steps of obtaining a patient gene expression dataset from a patient suspected of being infected with *Mycobacterium tuberculosis*; sorting the patient gene expression dataset into one or more gene modules associated with *Mycobacterium tuberculosis* infection; and comparing the patient gene expression dataset for each of the one or more gene modules to a gene expression dataset from a non-patient; wherein an increase or decrease in the totality of gene expression in the patient gene expression dataset for the one or more gene modules is indicative of active *Mycobacterium tuberculosis* infection.



WO 2011/066008 A3